Scholarlink

Background <p>Liver transplantation (LT) is a curative treatment for hepatocellular carcinoma (HCC), but access is often limited by organ shortage and prolonged waiting times. Living donor liver transplantation (LDLT) offers timely transplantation and may improve oncologic outcomes compared to deceased donor liver transplantation (DDLT).</p> Methods <p>This retrospective cohort study included 486 patients with HCC who underwent LT at two high-volume centers between 2010 and 2020. Outcomes were compared between LDLT and DDLT recipients. Survival analyses were performed using Kaplan–Meier estimates and Cox regression models.</p> Results <p>A total of 182 patients received LDLT and 304 received DDLT. Baseline tumor burden and liver function were comparable. LDLT was associated with shorter time to transplant (186 vs. 410&#xa0;days, <i>p</i> &lt; 0.001), fewer downstaging procedures, and improved survival. Five-year overall survival was 82% for LDLT versus 73% for DDLT (<i>p</i> = 0.010); disease-free survival was 93% versus 83% (<i>p</i> = 0.003). On multivariable analysis, DDLT (HR 3.03, <i>p</i> = 0.017) and BCLC B/C stage (HR 1.98, <i>p</i> = 0.017) were independent predictors of recurrence.</p> Conclusion <p>LDLT is associated with superior long-term outcomes in patients with HCC, independent of tumor stage and timing. These findings support the broader use of LDLT as an effective oncologic strategy.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term outcomes in deceased versus living donor liver transplantation for hepatocellular carcinoma: a bi-institutional study of 486 cases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月11日

查看全文
  • Fabrizio Di Benedetto,
  • Cristiano Guidetti,
  • Dimitri Aristotle Raptis,
  • Gian Piero Guerrini,
  • Paolo Magistri,
  • Massimo Malagò,
  • Stefano Di Sandro,
  • Dieter Clemens Broering

摘要

Background

Liver transplantation (LT) is a curative treatment for hepatocellular carcinoma (HCC), but access is often limited by organ shortage and prolonged waiting times. Living donor liver transplantation (LDLT) offers timely transplantation and may improve oncologic outcomes compared to deceased donor liver transplantation (DDLT).

Methods

This retrospective cohort study included 486 patients with HCC who underwent LT at two high-volume centers between 2010 and 2020. Outcomes were compared between LDLT and DDLT recipients. Survival analyses were performed using Kaplan–Meier estimates and Cox regression models.

Results

A total of 182 patients received LDLT and 304 received DDLT. Baseline tumor burden and liver function were comparable. LDLT was associated with shorter time to transplant (186 vs. 410 days, p < 0.001), fewer downstaging procedures, and improved survival. Five-year overall survival was 82% for LDLT versus 73% for DDLT (p = 0.010); disease-free survival was 93% versus 83% (p = 0.003). On multivariable analysis, DDLT (HR 3.03, p = 0.017) and BCLC B/C stage (HR 1.98, p = 0.017) were independent predictors of recurrence.

Conclusion

LDLT is associated with superior long-term outcomes in patients with HCC, independent of tumor stage and timing. These findings support the broader use of LDLT as an effective oncologic strategy.

Graphical abstract